VAXCYTE, INC. Payments to Acquire Debt Securities, Available-for-sale
VAXCYTE, INC. (PCVX) reported Payments to Acquire Debt Securities, Available-for-sale of $852.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $268.68M, a 23.03% decline year-over-year.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $584.13M, a 85.74% increase year-over-year.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $292.65M, a 64.10% decline year-over-year.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $255.31M, a 79.30% decline year-over-year.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.21B, a 60.75% decline from fiscal 2024.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $3.09B, a 132.10% increase from fiscal 2023.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $1.33B, a 1194.37% increase from fiscal 2022.
- VAXCYTE, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $102.75M, a 69.45% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $268.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $852.81M 10-Q · filed 2026-08-05 | $1.15B derived: sum of 3 quarters · filed 2026-08-05 | $1.40B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $584.13M 10-Q · filed 2026-05-06 | $876.78M derived: sum of 2 quarters · filed 2026-05-06 | $1.13B derived: sum of 3 quarters · filed 2026-05-06 | $1.48B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $292.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $547.96M derived: sum of 2 quarters · filed 2026-02-24 | $897.01M derived: sum of 3 quarters · filed 2026-08-05 | $1.21B 10-K · filed 2026-02-24 |
| 2025-09-30 | $255.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $604.37M derived: sum of 2 quarters · filed 2026-08-05 | $918.85M 10-Q · filed 2025-11-04 | $1.73B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $349.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $663.53M 10-Q · filed 2026-08-05 | $1.48B derived: sum of 3 quarters · filed 2026-08-05 | $2.71B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $314.49M 10-Q · filed 2026-05-06 | $1.13B derived: sum of 2 quarters · filed 2026-05-06 | $2.36B derived: sum of 3 quarters · filed 2026-05-06 | $2.71B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $815.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.05B derived: sum of 2 quarters · filed 2026-02-24 | $2.40B derived: sum of 3 quarters · filed 2026-02-24 | $3.09B 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.23B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.58B derived: sum of 2 quarters · filed 2025-11-04 | $2.27B 10-Q · filed 2025-11-04 | $2.48B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $350.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.04B 10-Q · filed 2025-08-06 | $1.24B derived: sum of 3 quarters · filed 2026-02-24 | $1.45B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $687.70M 10-Q · filed 2025-05-07 | $891.31M derived: sum of 2 quarters · filed 2026-02-24 | $1.10B derived: sum of 3 quarters · filed 2026-02-24 | $1.53B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $203.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $413.28M derived: sum of 2 quarters · filed 2026-02-24 | $846.12M derived: sum of 3 quarters · filed 2026-02-24 | $1.33B 10-K · filed 2026-02-24 |
| 2023-09-30 | $209.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $642.51M derived: sum of 2 quarters · filed 2024-11-05 | $1.13B 10-Q · filed 2024-11-05 | $1.20B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $432.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $916.61M 10-Q · filed 2024-08-06 | $987.90M derived: sum of 3 quarters · filed 2025-02-25 | $1.01B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $483.78M 10-Q · filed 2024-05-08 | $555.06M derived: sum of 2 quarters · filed 2025-02-25 | $572.65M derived: sum of 3 quarters · filed 2025-02-25 | $579.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $71.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $88.88M derived: sum of 2 quarters · filed 2025-02-25 | $95.77M derived: sum of 3 quarters · filed 2025-02-25 | $102.75M 10-K · filed 2025-02-25 |
| 2022-09-30 | $17.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $24.49M derived: sum of 2 quarters · filed 2023-11-06 | $31.46M 10-Q · filed 2023-11-06 | $72.52M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $13.87M 10-Q · filed 2023-08-08 | $54.93M derived: sum of 3 quarters · filed 2024-02-27 | $121.68M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $6.97M 10-Q · filed 2023-05-08 | $48.03M derived: sum of 2 quarters · filed 2024-02-27 | $114.78M derived: sum of 3 quarters · filed 2024-02-27 | $171.17M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $41.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $107.81M derived: sum of 2 quarters · filed 2024-02-27 | $164.20M derived: sum of 3 quarters · filed 2024-02-27 | $336.34M 10-K · filed 2024-02-27 |
| 2021-09-30 | $66.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $123.13M derived: sum of 2 quarters · filed 2022-11-07 | $295.28M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $56.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $228.53M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $172.15M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |